MapLight Therapeutics (MPLT) Cash & Equivalents (2024 - 2025)
MapLight Therapeutics' (MPLT) quarterly Cash & Equivalents came in at $46.7 million in Q4 2025, up 22.16% year-on-year from $38.3 million in Q4 2024, and down 27.15% quarter-over-quarter from $64.1 million in Q3 2025.
MapLight Therapeutics (MPLT) Cash & Equivalents (2024 - 2025) Analysis & Trends
MapLight Therapeutics has disclosed Cash & Equivalents across 2 years of filings, most recently posting $46.7 million for Q4 2025.
- Cash & Equivalents for Q4 2025 came in at $46.7 million, up 22.16% year-over-year; the trailing twelve-month figure through Dec 2025 was $46.7 million (up 22.16% YoY), and the FY2025 annual result was $46.7 million, up 22.16% from the prior year.
- Cash & Equivalents came in at $46.7 million for Q4 2025 at MapLight Therapeutics, down from $64.1 million in the prior quarter.
- In the past five years, Cash & Equivalents ranged from a high of $64.1 million in Q3 2025 to a low of $38.3 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 32.30 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 1.91 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 286.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 18.44 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 2.77 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 7.15 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 5.49 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 558.94 Mn |
| 10 | MapLight Therapeutics | 248.88 Mn | 248.88 Mn | - | 46.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 46.73 Mn |
| Sep 30, 2025 | 64.15 Mn |
| Dec 31, 2024 | 38.25 Mn |